問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Urology

Division of Thoracic Medicine

Division of Urology

Digestive System Department

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy) (在職)

Division of Urology

Division of Urology

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Urology

Division of Hematology & Oncology

更新時間:2023-09-19

劉明哲LIU, MING-CHE
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

篩選

List

45Cases

2013-10-01 - 2014-03-01

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-11-15 - 2022-12-15

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2025-04-01 - 2026-04-01

Others

Not yet recruiting
劑量調定的維生素D增補策略對馬拉松比賽後免疫功能與肌肉損傷的影響
  • Condition/Disease

    免疫功 能與肌肉損傷

  • Test Drug

    injection

Participate Sites
1Sites

Recruiting1Sites

2020-05-18 - 2023-12-31

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated Recurrent Urinary Tract Infections (rUTIs) in Women
  • Condition/Disease

    Recurrent Urinary Tract Infections (rUTIs)

  • Test Drug

    U101

Participate Sites
19Sites

Not yet recruiting7Sites

Recruiting6Sites

Terminated6Sites

2016-08-01 - 2019-07-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2025-01-15 - 2027-12-31

Phase I

Not yet recruiting
一項 I/II 臨床試驗以評估異體來源之臍帶幹細胞(GL-N-CP0002)合併 A 型肉毒桿菌毒素注 射療法對於腦性麻痺患者的安全性與療效性
  • Condition/Disease

    腦性麻痺患者

  • Test Drug

    injection

Participate Sites
2Sites

Recruiting2Sites

2017-11-01 - 2022-12-31

Phase I/II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2025-09-01 - 2029-12-31

Phase II

Not yet recruiting
A Phase 2, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V540A in Healthy Females 16 to 26 Years of Age
  • Condition/Disease

    Healthy Females

  • Test Drug

    Injection

Participate Sites
6Sites

Recruiting6Sites

2022-07-01 - 2024-03-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2017-01-01 - 2017-12-31

Phase I

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3 4 5